Skip to main content
Premium Trial:

Request an Annual Quote

NCI Awards Integral Molecular $150K to ID Cancer Biomarkers

NEW YORK (GenomeWeb News) – Integral Molecular said today that the National Cancer Institute has awarded it a $150,000 contract to map epitopes for monoclonal antibodies directed against cancer biomarkers.

Integral, based in Philadelphia, will analyze protein targets of interest to the clinical cancer proteomics community using shotgun mutagenesis mapping technology to identify amino acids essential for antibody binding and to discover and characterize cancer-specific biomarkers.

During the first phase of the project, which is fully funded by NCI, Integral said it will epitope map antibodies generated against claudin membrane proteins involved in several types of cancer.

Shotgun mutagensis is a method for mapping epitopes by rapidly evaluating the effects of point mutations across an entire target protein. Using a patented high-throughput expression method, thousands of point mutations are simultaneously evaluated for functional protein activity, Integral said.

The approach is particular well-suited to cancer biomarkers, many of which are complex membrane proteins that are resistant to direct structural analysis, the company said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.